GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (OTCPK:AONC) » Definitions » Debt-to-EBITDA

AONC (American Oncology Network) Debt-to-EBITDA : 11.35 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is American Oncology Network Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

American Oncology Network's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $13 Mil. American Oncology Network's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $134 Mil. American Oncology Network's annualized EBITDA for the quarter that ended in Jun. 2024 was $13 Mil. American Oncology Network's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 11.35.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for American Oncology Network's Debt-to-EBITDA or its related term are showing as below:

AONC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.26   Med: 5.51   Max: 8.11
Current: -2.82

During the past 4 years, the highest Debt-to-EBITDA Ratio of American Oncology Network was 8.11. The lowest was -3.26. And the median was 5.51.

AONC's Debt-to-EBITDA is ranked worse than
100% of 444 companies
in the Healthcare Providers & Services industry
Industry Median: 2.405 vs AONC: -2.82

American Oncology Network Debt-to-EBITDA Historical Data

The historical data trend for American Oncology Network's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Oncology Network Debt-to-EBITDA Chart

American Oncology Network Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
- 8.11 5.51 -3.26

American Oncology Network Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only - -1.40 -1.98 -2.03 11.35

Competitive Comparison of American Oncology Network's Debt-to-EBITDA

For the Medical Care Facilities subindustry, American Oncology Network's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Oncology Network's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, American Oncology Network's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where American Oncology Network's Debt-to-EBITDA falls into.



American Oncology Network Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

American Oncology Network's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(7.881 + 120.444) / -39.351
=-3.26

American Oncology Network's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(12.512 + 134.408) / 12.948
=11.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.


American Oncology Network  (OTCPK:AONC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


American Oncology Network Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of American Oncology Network's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


American Oncology Network Business Description

Traded in Other Exchanges
N/A
Address
10485 NE 6th Street, Unit 3930, Bellevue, WA, USA, 98004
American Oncology Network Inc Formerly American Oncology Network LLC is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services through 24 oncology practices located in Arkansas, Louisiana, Indiana, Virginia, Ohio, Nevada, Iowa, Missouri, Washington, North Carolina, Michigan, Maryland, South Carolina, Arizona, and Georgia. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services.
Executives
Saba Capital Management, L.p. 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
David H Gould officer: Chief Financial Officer 7370 COLLEGE PARKWAY, SUITE 207, FORT MEYERS FL 33907
Erica Mallon officer: General Counsel 14543 GLOBAL PARKWAY, SUITE 110, FORT MEYERS FL 33913
Shalin Shah director 3402 W DR. MARTIN LUTHER KING JR. BLVD, TAMPA FL 33607
Vipul M Patel director 11704 SE 15TH CIRCLE, OCALA FL 34480
Todd Schonherz director, officer: Chief Executive Officer 14543 GLOBAL PARKWAY, 2ND FLOOR, FORT MEYERS FL 33913
Stephen Divers director, officer: Chief Medical Officer 133 HARMONY PARK CIRCLE, HOT SPRINGS AZ 71913
Vance Wright-browne director 22395 EDGEWATER DRIVE, PORT CHARLOTTE FL 33980
James Stith director ONE LETTERMAN DRIVE, CM200, SAN FRANCISCO CA 94129
Aea Growth Equity Fund Lp 10 percent owner 520 MADISON AVE, 40TH FLOOR, NEW YORK NY 10022
Aea Growth Equity Fund (parallel) Lp 10 percent owner 520 MADISON AVE, 40TH FLOOR, NEW YORK NY 10022
Ravi Yang Sarin director C/O ARES MANAGEMENT LLC, 2000 AVENUE OF THE STARS, 12TH FLOOR, LOS ANGELES CA 90067
Brian R Hoesterey 10 percent owner C/O AEA INVESTORS LP, 666 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10103
Kevin Nazemi director, officer: Chief Executive Officer 10485 NE 6TH ST, UNIT 3930, BELLEVUE WA 98004